Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study.

Date publication

avril 2023

Journal

Cardiovascular and interventional radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GANGI Afshin

Tous les auteurs :
Levy J, David E, Hopkins T, Morris J, Tran ND, Farid H, Massari F, O'Connell WG, Vogel A, Gangi A, Sunenshine P, Dixon R, Von der Höh N, Bagla S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37012392

Résumé

The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.

Mots clés

Ablation, Osseous metastases, RFA, Radiation-induced fracture, Skeletal-related events

Référence

Cardiovasc Intervent Radiol. 2023 04 3;: